<?xml version='1.0' encoding='utf-8'?>
<document id="18363538"><sentence text="Potential glucosamine-warfarin interaction resulting in increased international normalized ratio: case report and review of the literature and MedWatch database."><entity charOffset="10-21" id="DDI-PubMed.18363538.s1.e0" text="glucosamine" /></sentence><sentence text="We describe a 71-year-old man who had received warfarin 7" /><sentence text="5 mg/day for 5 years for atrial fibrillation, which had maintained his international normalized ratio (INR) within a narrow range of 2" /><sentence text="5-3" /><sentence text="2" /><sentence text=" During this 5-year period, he had also been treating himself with the supplement glucosamine hydrochloride 500 mg-chondroitin sulfate 400 mg twice/day for arthritis"><entity charOffset="82-107" id="DDI-PubMed.18363538.s6.e0" text="glucosamine hydrochloride" /></sentence><sentence text=" The patient then increased his dosage of glucosamine to 1500 mg and chondroitin to 1200 mg twice/day; his INR previous to this change was 2"><entity charOffset="42-53" id="DDI-PubMed.18363538.s7.e0" text="glucosamine" /></sentence><sentence text="3" /><sentence text=" Approximately 3 weeks later, his INR increased to 3" /><sentence text="9" /><sentence text=" His supplement dosage was reduced to glucosamine 750 mg-chondroitin 600 mg/day; a repeat INR done 16 days later was 4"><entity charOffset="38-49" id="DDI-PubMed.18363538.s11.e0" text="glucosamine" /></sentence><sentence text="7" /><sentence text=" The supplement was then stopped, and his warfarin schedule was changed to 7" /><sentence text="5 mg every other day alternating with 3" /><sentence text="75 mg every other day" /><sentence text=" Sixteen days later, his INR was 2" /><sentence text="6" /><sentence text=" This case report suggests that a potential interaction exists between warfarin and glucosamine that is associated with an increase in the INR"><entity charOffset="84-95" id="DDI-PubMed.18363538.s18.e0" text="glucosamine" /></sentence><sentence text=" We therefore performed a pharmacovigilance survey of spontaneously reported adverse events in warfarin-treated patients concomitantly exposed to glucosamine, glucosamine-chondroitin sulfate, or chondroitin sulfate and present a literature review of this apparent drug-drug interaction"><entity charOffset="146-157" id="DDI-PubMed.18363538.s19.e0" text="glucosamine" /><entity charOffset="159-170" id="DDI-PubMed.18363538.s19.e1" text="glucosamine" /><entity charOffset="171-190" id="DDI-PubMed.18363538.s19.e2" text="chondroitin sulfate" /><entity charOffset="195-214" id="DDI-PubMed.18363538.s19.e3" text="chondroitin sulfate" /><pair ddi="false" e1="DDI-PubMed.18363538.s19.e0" e2="DDI-PubMed.18363538.s19.e0" /><pair ddi="false" e1="DDI-PubMed.18363538.s19.e0" e2="DDI-PubMed.18363538.s19.e1" /><pair ddi="false" e1="DDI-PubMed.18363538.s19.e0" e2="DDI-PubMed.18363538.s19.e2" /><pair ddi="false" e1="DDI-PubMed.18363538.s19.e0" e2="DDI-PubMed.18363538.s19.e3" /><pair ddi="false" e1="DDI-PubMed.18363538.s19.e1" e2="DDI-PubMed.18363538.s19.e1" /><pair ddi="false" e1="DDI-PubMed.18363538.s19.e1" e2="DDI-PubMed.18363538.s19.e2" /><pair ddi="false" e1="DDI-PubMed.18363538.s19.e1" e2="DDI-PubMed.18363538.s19.e3" /><pair ddi="false" e1="DDI-PubMed.18363538.s19.e2" e2="DDI-PubMed.18363538.s19.e2" /><pair ddi="false" e1="DDI-PubMed.18363538.s19.e2" e2="DDI-PubMed.18363538.s19.e3" /></sentence><sentence text=" Using the United States Food and Drug Administration (FDA) MedWatch database, 20 reports of glucosamine or glucosamine-chondroitin sulfate use with warfarin associated with altered coagulation (manifested by increased INR, or increased bleeding or bruising) were identified"><entity charOffset="93-104" id="DDI-PubMed.18363538.s20.e0" text="glucosamine" /><entity charOffset="108-119" id="DDI-PubMed.18363538.s20.e1" text="glucosamine" /><pair ddi="false" e1="DDI-PubMed.18363538.s20.e0" e2="DDI-PubMed.18363538.s20.e0" /><pair ddi="false" e1="DDI-PubMed.18363538.s20.e0" e2="DDI-PubMed.18363538.s20.e1" /></sentence><sentence text=" In some cases, a decrease in the supplement dosage was followed by a return of the INR to the previous therapeutic range" /><sentence text=" Similarly, a decrease in warfarin dosage was followed by a decrease in INR in one patient who received long-term warfarin therapy" /><sentence text=" One report described an intraventricular bleed and subdural hematoma, which resulted in a persistent vegetative state" /><sentence text=" The World Health Organization (WHO) adverse drug reactions database documented 21 spontaneous reports of increased INR associated with glucosamine use, 17 of which resolved when glucosamine was stopped"><entity charOffset="136-147" id="DDI-PubMed.18363538.s24.e0" text="glucosamine" /><entity charOffset="179-190" id="DDI-PubMed.18363538.s24.e1" text="glucosamine" /><pair ddi="false" e1="DDI-PubMed.18363538.s24.e0" e2="DDI-PubMed.18363538.s24.e0" /><pair ddi="false" e1="DDI-PubMed.18363538.s24.e0" e2="DDI-PubMed.18363538.s24.e1" /></sentence><sentence text=" We located one published case report of concomitant use of glucosamine-chondroitin sulfate potentiating the effect of warfarin"><entity charOffset="60-71" id="DDI-PubMed.18363538.s25.e0" text="glucosamine" /><entity charOffset="119-127" id="DDI-PubMed.18363538.s25.e1" text="warfarin" /><pair ddi="false" e1="DDI-PubMed.18363538.s25.e0" e2="DDI-PubMed.18363538.s25.e0" /><pair ddi="false" e1="DDI-PubMed.18363538.s25.e0" e2="DDI-PubMed.18363538.s25.e1" /></sentence><sentence text=" In aggregate, the reports from the FDA and WHO, the published case report, and our case report suggest that the use of warfarin and glucosamine may lead to an increased INR"><entity charOffset="120-128" id="DDI-PubMed.18363538.s26.e0" text="warfarin" /><entity charOffset="133-144" id="DDI-PubMed.18363538.s26.e1" text="glucosamine" /><pair ddi="false" e1="DDI-PubMed.18363538.s26.e0" e2="DDI-PubMed.18363538.s26.e0" /><pair ddi="false" e1="DDI-PubMed.18363538.s26.e0" e2="DDI-PubMed.18363538.s26.e1" /></sentence><sentence text=" Patients should be advised that the use of the two products may cause an increase in INR, and they should inform their health care provider if they consume glucosamine"><entity charOffset="157-168" id="DDI-PubMed.18363538.s27.e0" text="glucosamine" /></sentence><sentence text=" More information is necessary to define this interaction" /><sentence text="" /></document>